Inclusion Criteria:

1. Patients with adenocarcinoma of the prostate that in the opinion of the surgeon could
be resectable after response to systemic therapy. Ductal carcinoma variant is
included.

2. All patients must be regarded as acceptable anesthetic risk for radical prostatectomy
and confirm their intention to undergo radical prostatectomy at the end of the
neoadjuvant therapy.

3. Zubrod performance status 2 or better.

4. All patients must have thorough tumor staging and meet one of the following criteria:
a) Either lymph node biopsy or lymph node dissection demonstrating presence of lymph
node metastasis. b) Pelvic or retroperitoneal lymphadenopathy >/= 2.0 cm visualized
on CT scan (biopsy is not required if >/= 2.0 cm and in typical distribution) c)
Primary tumor Gleason score >/= 8 and serum PSA concentration >/= 25 ng/ml,
indicating high risk of occult lymph node metastases.

5. (# 4 cont'd) d) Primary tumor stage T3 and Gleason score >/= 7, indicating high risk
of occult lymph node metastases. e) Primary tumor stage T4 indicating high risk of
occult lymph node metastases.

6. Prior hormonal therapy up to 6 months is permitted. No concurrent ketoconazole is
permitted.

7. Patients must have adequate bone marrow function defined as an absolute peripheral
granulocyte count of > 1,500/mm^3 and platelet count of > 100,000/mm^3; adequate
hepatic function defined with a total bilirubin of < 1.5 mg/dl and AST/ALT < 2X the
upper limits of normal; adequate renal function defined as serum creatinine clearance
> 40 cc/min (measured or calculated).

8. Patients must sign an informed consent indicating that they are aware of the
investigational nature of this study, in keeping with the policies of the
institution.

9. All patients must be evaluated in the Department of Urology and Department of
Genitourinary Medical Oncology prior to signing informed consent.

Exclusion Criteria:

1. Patients with small cell or sarcomatoid histology.

2. Patients with clinical or radiological evidence of bone or other extranodal
metastasis (M1b or M1c).

3. Prior chemotherapy.

4. Patients with severe or uncontrolled intercurrent infection.

5. Patients with NYHA Class III/IV congestive heart failure, unstable angina or history
of myocardial infarction within the last 6 months.

6. Contraindications to corticosteroids.

7. Uncontrolled severe hypertension, persistently uncontrolled diabetes mellitus,
oxygen-dependent lung disease, chronic liver disease or HIV infection.

8. Second malignancies (excluding non-melanoma skin cancer) unless disease-free for 3
years.

9. Overt psychosis, mental disability or otherwise incompetent to give informed consent.